Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation-Reference-Cited by-同舟云学术

Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation

Published:2020-04-11 Issue:1 Volume:10 Page:65-72
ISSN:2411-4634
Container-title:Head and Neck Tumors (HNT)
language:
Short-container-title:Opuholi golovy i šei

Author:

Borodavina E. V.¹^ORCID,Isaev P. A.¹,Shurinov A. Yu.¹^ORCID,Rumyantsev P. O.²^ORCID,Krylov V. V.¹,Petrosyan K. M.¹^ORCID,Kaprin A. D.¹^ORCID,Ivanov S. A.¹^ORCID,Podvyaznikov S. O.³^ORCID,Romanov I. S.⁴^ORCID,Mudunov A. M.⁴^ORCID,Slashchuk K. Yu.²^ORCID,Zhikhorev R. S.⁵,Volkonsky M. V.⁵,Chagova R. M.⁶,Suslova I. R.⁷,Khryapa A. I.⁸,Lepshokova A. Kh.⁹,Fadeeva N. L.¹⁰,Safarova A. R.¹¹,Kaleykina L. P.¹²,Lymar E. V.¹³,Chernyakova E. M.¹⁴,Snezhko O. A.⁹,Zinkovskaya A. E.¹⁵,Mufazalov F. F.¹⁶,Kuzmina E. S.¹⁷,Druzhinina Yu. V.¹⁸,Musin Sh. I.¹⁶,Mukhitova M. R.¹¹,Khasanova A. I.¹¹,Safina S. Z.¹¹,Kirienko S. L.³

Affiliation:

1. A. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

2. National Medical Research Center for Endocrinology, Ministry of Health of Russia

3. Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

4. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

5. Moscow City Oncology Hospital No. 62, Moscow Healthcare Department

6. S.P. Botkin City Clinical Hospital, Moscow Healthcare Department

7. Oncological Dispensary No. 4, Moscow Healthcare Department

8. Saint Petersburg Clinical Scientific and Practical Center for Specialised Types of Medical Care (Oncological)

9. Oncological Dispensary of Rostov Region

10. S.G. Primushko Republican Clinical Oncologic Dispensary, Ministry of Health of the Udmurt Republic

11. Republican Clinical Oncological Dispensary, Ministry of Health of the Tatarstan

12. Republican Clinical Oncological Dispensary of the Republic of Mordovia

13. Clinical Oncology Dispensary No. 1, Ministry of Health of Krasnodar Region

14. Republican Oncological Dispensary of the Republic of Karelia

15. 5City Clinical Oncology Dispensary

16. Republican Clinical Oncological Dispensary, Ministry of Health of the Republic of Bashkortostan

17. Regional Cancer Center, Salekhard District Clinical Hospital

18. Multidisciplinary Clinical Medical Center “Medical City”

Abstract

Background. The implementation of tyrosine kinase inhibitors into clinical practice improved treatment outcomes in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC). Lenvatinib is recommended as a first-line drug for these patients. The study objective is to analyze clinical experience with lenvatinib in patients with RR-DTC in the Russian Federation. Materials and methods. The data from 18 clinical sites in Russia was analyzed for the period December 2015 and September 2019. Seventyseven patients with histologically verified DTC, proven resistance to radioactive iodine therapy, and tumor progression (according to the Response Evaluation Criteria In Solid Tumors 1.1 criteria) were included in the study. Results.Median progression-free survival in patients included into analysis (n = 72) was 26.1 months. In patients who responded to therapy (including those with partial and complete response), median progression-free survival reached 36.2 months, which is higher than that reported in the updated results of the SELECT study (33.1 months). Lenvatinib-associated adverse events (AEs) were observed in 87 % of patients. Severe AEs were registered in 18.2 % of participants. In 6.5 % of cases, AEs lead to lenvatinib cessation; in 74 % of cases, AEs required dose reduction.Conclusion. Our findings suggest high efficacy and good tolerability of lenvatinib in patients with RR-DTC in routine clinical practice in the Russian Federation.

Publisher

Publishing House ABV Press

Subject

Pharmacology (medical),Cancer Research,Radiology Nuclear Medicine and imaging,Oncology,Otorhinolaryngology,Surgery

Reference13 articles.

1. Состояние онкологической помощи населению России в 2018 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2019. 236 c. [State of cancer care in Russia in 2018. Ed. by A.D. Kaprin, V.V. Starinsky, G.V. Petrova. Moscow, 2019. 236 р. (In Russ.)].

2. Румянцев П.О., Фомин Д.К., Румянцева У.В. Критерии радиойодрезистентности высокодифференцированного рака щитовидной железы к терапии радиоактивным йодом. Опухоли головы и шеи 2014;(3):4–9. [Rumyantsev P.O., Fomin D.K., Rumyantseva U.V. Сriteria of well-differentiated thyroid carcinoma resistance to radioiodine therapy. Opukholi golovy i shei = Head and Neck Tumors 2014;(3):4–9. (In Russ.)]. DOI: 10.17650/2222-1468-2014-0-3-4-9.

3. Нечаева О.А., Бавыкина Л.Г., Древаль А.В. Дифференцированный рак щитовидной железы: современные подходы к диагностике, терапии и динамическому наблюдению (обзор). Русский медицинский журнал 2016;(1):9–12. [Nechaeva O.A., Bavykina L.G., Dreval A.V. Differentiated thyroid cancer: modern approaches to diagnosis, therapy and dynamic monitoring (review). Russky meditsinky zhurnal = Russian Medical Journal 2016;(1):9–12. (In Russ.)].

4. Brose M.S., Nutting C.M., Jarzab B. et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384(9940):319–28. DOI: 10.1016/S0140-6736(14)60421-9.

5. Schlumberger M., Tahara M., Wirth L.J. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015;372(7):621–30. DOI: 10.1056/NEJMoa1406470.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survival analysis of patients with advanced metastatic differentiated thyroid cancer;Head and Neck Tumors (HNT);2022-08-01

2. Historical aspects and modern concepts in the treatment of patients with differentiated thyroid cancer, refractory to radioactive iodine therapy;Head and Neck Tumors (HNT);2022-02-14

3. On the role of autophagy in the progression of differentiated thyroid cancer (literature review);Siberian journal of oncology;2022-01-13

4. Late toxicities burden in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib;Endocrine;2021-04-02